Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27604070 | 0.85 | TRPV1 (0.34) | TRPV1NT5EL3MBTL1 | |
| SCHEMBL4485875 | 0.82 | KMT2A (0.39) | TRPV1NT5EL3MBTL1TRPV4P2RX7 | |
| SCHEMBL30910910 | 0.82 | KMT2A (0.39) | TRPV1NT5EL3MBTL1TRPV4P2RX7 | |
| SCHEMBL1742466 | 0.81 | TRPV1 (0.37) | TRPV1NT5EL3MBTL1TRPV4P2RX7 | |
| SCHEMBL12266190 | 0.81 | TRPV1 (0.40) | TRPV1L3MBTL1P2RX7MEN1KMT2A | |
| SCHEMBL9952737 | 0.81 | LOXL2 (0.38) | TRPV1NT5EL3MBTL1TRPV4P2RX7 | |
| SCHEMBL29464837 | 0.81 | TRPV1 (0.37) | TRPV1NT5EL3MBTL1TRPV4P2RX7 | |
| SCHEMBL21503692 | 0.80 | TRPV1 (0.40) | TRPV1L3MBTL1MEN1KMT2A | |
| SCHEMBL13697560 | 0.78 | TRPV1 (0.38) | TRPV1NT5ETRPV4P2RX7KDM4E | |
| SCHEMBL14920971 | 0.78 | TAAR1 (0.37) | TRPV1L3MBTL1P2RX7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | TRPV1 769/4885NT5E 895/4885L3MBTL1 3408/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | TRPV1 769/4885NT5E 895/4885L3MBTL1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.